Table 1.
Demographic and Clinical Data in 2 Genotype Groups of rs2514218
| C/C Homozygotes (n = 56) | T Carriers (n = 44) | P Values | |
|---|---|---|---|
| Male sex, n (%) | 41 (73.2) | 34 (77.3) | .64 |
| Age (y), mean ± SD | 21.4±5.1 | 21.8±5.0 | .69 |
| Medication (aripiprazole), n (%) | 29 (51.8) | 20 (45.5) | .53 |
| Race, n (%) | .06 | ||
| Asian | 2 (3.6) | 3 (6.8) | |
| African American | 30 (53.6) | 11 (25.0) | |
| Hispanic | 6 (10.7) | 8 (18.2) | |
| Caucasian | 15 (26.8) | 20 (45.5) | |
| Others | 3 (5.4) | 2 (4.5) | |
| Schizophrenia diagnosis, n (%) | 38 (67.8) | 26 (59.1) | .41 |
| BPRS total scores, mean ± SD | 45.4±7.4 | 44.0±8.7 | .37 |
| Duration of untreated psychosis (wk), mean ± SD | 128.8±221.8 | 90.7±110.7 | .30 |
| Medication dose (level)a | 3.3±1.4 | 2.9±1.2 | .12 |
| Treatment responderb, n (%) | 32 (57.1) | 21 (47.7) | .35 |
| Comedications | |||
| Benzodiazepine use, % | 44.6 | 56.8 | .23 |
| Anticholinergics use, % | 21.4 | 25.0 | .67 |
| Beta-blocker use, % | 8.9 | 13.6 | .46 |
Note: BPRS, Brief Psychiatric Rating Scale.
aFor medication dose, levels 1–6 represented 1, 2, 3, 4, 5, and 6mg/d for risperidone and 5, 10, 15, 20, 25, and 30mg/d for aripiprazole, respectively.
bTreatment response: response criteria required (1) a rating of 3 (“mild”) or less on all of the following items of the BPRS: conceptual disorganization, grandiosity, hallucinatory behavior, and unusual thought content and (2) a Clinical Global Impression Scale-Improvement rating of much or very much improved on 2 consecutive rating assessments (this issue).13